ReviewAustralian prescriber2020
Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
Review in Australian prescriber, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Heterozygous X-linked Alport syndrome in a pregnant woman: A case report.SAGE open medical case reports · 2026Article
- Review
- Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.Veterinary medicine and science · 2024Article
- Review
- Observational
- Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options.Molecules (Basel, Switzerland) · 2023Review
- Diuretics in the management of chronic heart failure: when and how.Australian prescriber · 2022Review
- Sodium-glucose co-transporter 2 inhibitors beyond diabetes.Australian prescriber · 2022Review
- Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2-Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS ARE ORAL GLUCOSE-LOWERING DRUGS THAT INCREASE THE URINARY EXCRETION OF GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE THEY REDUCE ALL-CAUSE MORTALITY CARDIAC MORTALITY RATES OF HOSPITALISATION FOR HEART FAILURE AND THE PROGRESSION OF RENAL DISEASE: THERE ARE ADVERSE EFFECTS RELATED TO THE MECHANISM OF ACTION THESE INCLUDE POLYURIA AND INTRAVASCULAR VOLUME DEPLETION FROM OSMOTIC DIURESIS AND GENITOURINARY INFECTIONS FROM GLYCOSURIA KETOACIDOSIS IS A RARE ADVERSE EFFECT: THE GLUCOSE-LOWERING EFFICACY OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS DECREASES WITH INCREASING RENAL IMPAIRMENT:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.